在生殖潜力的妇女中使用瓦尔酸:万能药或潘多拉的盒子
Kiren George Koshy1, Mary Iype2
1Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India.
Neurology India
|September 14, 2025
概括
药物瓦尔酸带来了诸如出生缺陷 (8-15%) 和不孕症等风险. 切换到替代药物可能会导致发作复发 (20%),需要仔细的患者和医生讨论.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 生殖健康 生殖健康
背景情况:
- 瓦尔酸是一种广泛的抗发作药物治疗.
- 它带有显著的风险,包括产性 (8-15%的风险),肝毒性,胰腺炎和两性不育.
- 监管限制限制了其使用,特别是在生殖潜力的女性中.
研究的目的:
- 审查酸在管理中的作用.
- 强调与烯酸相关的风险,特别是对于生育年龄的女性.
- 讨论当前的法规以及转向替代品时共享决策的重要性.
主要方法:
- 这是一个复习文章.
- 它综合了来自治疗指南和怀孕登记册的信息.
- 专注于烯酸与替代品的风险效益分析.
主要成果:
- 瓦尔酸的使用与8-15%的产性风险有关.
- 从酸转换为诸如 levetiracetam或lamotrigine之类的替代品,发作复发或恶化的风险为~20%.
- 影响复发风险的因素包括的缓解时间,酸剂量,类型和性恶化.
结论:
- 瓦尔酸的风险需要仔细考虑,特别是在生育年龄的妇女身上.
- 切换需要彻底的沟通和共享决策,以平衡原风险与控制.
- 替代药物和监管指南旨在减轻风险,同时有效管理.
相关概念视频
Teratogenicity
3.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K
Mitral Valve Prolapse III: Nursing Management
252
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
252
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
785
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
785
Hormonal Regulation of the Menstrual Cycle
1.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
1.4K
Antiepileptic Drugs: Potassium Channel Activators
586
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
586
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
557
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
557


